INTRODUCTION
A large (410-fold) interindividual variation in the dose requirement of warfarin to achieve optimal therapeutic anticoagulation responses has often posed difficulties for clinicians to individualize warfarin doses to their patients. In addition, therapeutic targets measured by international normalized ratio (INR) of prothrombin time appear to differ between populations: INR of 2-3 for most indications in Caucasian patients 1 and 1.5-2.5 for Asian patients. 2, 3 In this context, there is a strong demand to clarify concealed factors associated with a substantial interindividual variability of anticoagulation responses to warfarin. It is widely recognized that pharmacokinetic and pharmacodynamic factors contribute to the intra-and interindividual variabilities in the dosage requirement of warfarin. Clinically available warfarin is a racemic mixture of (R)-and (S)-warfarin and the anticoagulation effect of (S)-warfarin is three to five times more potent than (R)-warfarin. 4 Therefore, the interindividual variability in the disposition of (S)-warfarin would be the most important pharmacokinetic parameter associated with variable anticoagulation responses to warfarin. (S)-warfarin is metabolized almost exclusively by CYP2C9 to its major metabolite, (S)-7-hydroxywarfarin in humans. 5 According to the physiological model, 6 the steady-state unbound plasma concentrations (C u ) of an orally administered drug being eliminated mainly by hepatic metabolism depend solely on the hepatic intrinsic clearance (CL int,h ) for the drug. This pharmacokinetic parameter represents the hepatic enzyme activity involved in the metabolism of the drug. Collectively, the hepatic CYP2C9 activity would be one of the most critical determinants of the interindividual variability in the anticoagulation response to warfarin.
Genetic polymorphisms of CYP2C9 have been extensively studied in the connection with the alterations in enzyme activity. Among the 11 variant alleles of CYP2C9 so far reported, 7 CYP2C9*2 and CYP2C9*3 would be most important in the light of their influence on in vitro and in vivo metabolic activities and allelic frequencies in different ethnic populations. [8] [9] [10] [11] [12] [13] [14] [15] CYP2C9*4 16 has been detected so far in only one Japanese patient whose phenytoin clearance was shown to be substantially reduced as compared with those possessing CYP2C9*1/*1. The allelic frequency of this variant should be very low in Japanese and no information is available in Caucasian and African-American populations. CYP2C9*5 was detected in five of 110 African-American 17 and three of 183 Tanzanians, 18 but none in Caucasian or Asians. Although no information is available for the in vivo enzyme activity of CYP2C9*5 at present, recombinant proteins of CYP2C9*5 and CYP2C9*4 exhibited markedly reduced enzyme activities as compared with that of the wild-type CYP2C9 in vitro. 17, 19 While the allelic frequency of CYP2C9*6, 20 a null allele of CYP2C9, has been shown to be 0.6% in African-American, none of the Caucasians or Asians have been shown to possess this variant allele. The finding that a homozygote of CYP2C9*6 developed severe phenytoin toxicity by an oral phenytoin dosing of 300 mg/day indicates that this allele would be associated with a substantially reduced in vivo enzyme activity. Among the six other newly discovered CYP2C9 variant alleles (ie, from CYP2C9*7 to CYP2C9*12),
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CYP2C9*11 (R335W) showed markedly defective metabolic activity in in vitro systems. Nonetheless, there is a paucity of information regarding the in vivo activities of these variants. Recently, different groups of investigators have reported the relation between CYP2C9 polymorphisms (ie, CYP2C9*2 and CYP2C9*3) and the daily dose requirement of warfarin and risks of bleeding complications during anticoagulation therapy. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] These studies support an idea that the genetic polymorphisms of CYP2C9 would contribute to the interindividual variability of the anticoagulation responses to warfarin along with the previously known clinical and environmental variables (eg, age, concomitantly administered drugs, foods and clinical indications). 33, 34 Our knowledge about pharmacodynamic factors associated with the variability in the anticoagulation of warfarin is relatively limited. Hereditary resistance to warfarin and to other analogous compounds has been reported in humans 35 and in a few strains of rodents. 36 The mechanism(s) of warfarin resistance in humans and rodents has been considered to have orthologous genetic underpinnings in the same enzyme complex (presumably a vitamin K 1 2,3,-epoxide reductase, VKOR) or related systems. 37 Recently, Wallin et al 38 demonstrated that VKOR partially purified from hereditary warfarin resistant rats showed no significant differences in the affinity constant (K m ), specific activity and sensitivity to warfarin as compared with that purified from normal rats. However, they found that the mRNA of calumenin was overexpressed in the liver of warfarinresistant rats compared with normal rats. 38 Calumenin belongs to the CREC family of Ca 2+ -binding proteins found in the various secretory pathways of mammalian cells and has chaperone functions in the endoplasmic reticulum. Wallin et al 38 suggested that calumenin may interfere with VKOR-supported g-carboxylase activity. This study may open a new avenue to elucidate genetic mechanism(s) associated with warfarin resistance and interindividual variability of warfarin sensitivity in humans.
While genetic polymorphisms of vitamin K-dependent coagulation factors (F-II, VII, IX, X Protein C, Protein S and g-glutamyl carboxylase) have also been studied intensively in the light of susceptibility to venous thrombosis, 39 only limited information is available regarding the relation between mutations in these coagulation proteins and the variability in the anticoagulation sensitivity to warfarin in humans. It has been speculated that the impact of genetic polymorphisms of vitamin K-dependent coagulation proteins on the interindividual variability of warfarin sensitivity may be less important than those of CYP2C9, 40 because the allelic frequencies of variants for coagulation proteins such as F-IX reported so far are much lower than those of CYP2C9. 41 In this context, we consider that the pharmacogenetics of CYP2C9 would be a principal factor involved in the interindividual variability in the anticoagulation response to warfarin. Thus, our goals of the present article are to summarize the clinical data on the relation between the CYP2C9 polymorphisms and the daily dose requirement of warfarin as well as the susceptibility to bleeding complications and to assess the impact of CYP2C9 polymorphisms on the pharmacokinetics of (S)-warfarin in different populations. In addition, we wish to give a comprehensive pharmacokinetic explanation why the patients carrying genetic polymorphisms associated with reduced CYP2C9 activity would have less stable INR status than those with the wild-type genotype particularly during the initial phase of warfarin therapy.
EFFECTS OF CYP2C9 GENOTYPES ON THE MAINTENANCE DOSE OF WAR-FARIN Caucasians
Furuya et al 22 were the first to report that patients with CYP2C9*2 allele required 20% lower maintenance dose of warfarin than those with the wildtype (CYP2C9*1) allele. Recently, Aithal et al 23 reported that patients requiring a lower dose of warfarin (ie, o1.5 mg/day) to maintain optimum anticoagulation had a higher incidence (81%) of having one or more CYP2C9 variant alleles (ie, CYP2C9*2 and CYP2C9*3) than those randomly selected from anticoagulation clinics (38%). Tables 1 and 2 summarize the data obtained from previous studies investigating the relation between the CYP2C9 genotypes and the maintenance daily dose of warfarin associated with therapeutic anticoagulation. Available data [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] agree with the notion that the stable maintenance dose of warfarin would differ significantly among the patients possessing distinct CYP2C9 genotypes and that the magnitude of impact by CYP2C9*3 variant on the dose requirement of warfarin would be greater than that by CYP2C9*2 variant.
The patients with the heterozygous CYP2C9*2 (CYP2C9*1/*2) and CYP2C9*3 (CYP2C9*1/*3) genotypes would require on average 21% (range, 14-27%) and 34% (range, 15-49%) lower daily maintenance dose of warfarin, respectively, as compared with those with the homozygous wild-type genotype (CYP2C9*1/*1). In addition, the patients with the homozygous mutation of CYP2C9*3 or with the combined heterozygous mutation of CYP2C9*2 and *3 (CYP2C9*2/*3) would require 60-75% lower doses of warfarin than those with the homozygous wild-type allele. 27, 31 Asians As none of the Asians so far studied were carriers of the CYP2C9*2 variant, it is impossible to assess the impact of this variant on the dose requirement of warfarin in Asians. While most of the previous studies [10] [11] [12] [13] [14] [15] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] agreed that the patients possessing at least one CYP2C9*3 variant would require a significantly lower maintenance dose of warfarin than those possessing the homozygous wild-type genotype (CYP2C9*1/*1) irrespective of their ethnic backgrounds, there is a discernible difference in the impact of CYP2C9*3 variant on the warfarin doses between the populations. While Japanese patients with the CYP2C9*1/ *3 and CYP2C9*3/*3 genotypes have 50 and 90% lower warfarin doses than those with the CYP2C9*1/*1 genotype, respectively, 12-14 the impact of CYP2C9*3 on the warfarin dose appeared somewhat attenuated in Caucasians. The Caucasian patients with the CYP2C9*1/*3 and CYP2C9*3/*3 genotypes have 20-45% and 75% lower warfarin doses than those with homozygous wild-type CYP2C9 genotype, respectively. 15, [24] [25] [26] [27] [28] [29] [30] [31] Anecdotal observations indicated that the maintenance doses of warfarin obtained from Asians (ie, 3.4 and 3.3 mg/day for Japanese [12] [13] [14] and Chinese, 32 respectively) are 20-50% lower than those obtained from Caucasian (ie, 4.1-6.7 mg/day). 10, 11, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] We will discuss whether or not the assumed population difference in the maintenance dose of warfarin between Caucasians and Asians can be explained by the population difference in the polymorphisms of CYP2C9 in the separate chapter.
CYP2C9 GENOTYPES AND SUSCEPT-IBILITY TO BLEEDING COMPLICA-TIONS Induction phase While the CYP2C9 polymorphism would influence on the interindividual variability of the maintenance dose of warfarin associated with optimal anticoagulation effect, it may also CYP2C9 polymorphisms and warfarin therapy H Takahashi and H Echizen influence on the susceptibility to bleeding complications. Aithal et al 23 reported that the patients requiring less than 1.5 mg/day of warfarin for attaining optimal INR (ie, the low-dose group) had a significantly greater probability of developing above-range or supratherapeutic INR defined as 44.0 during the induction phase of the warfarin therapy (odds ratio (OR), 5.97; 95% confidence interval (CI), 2.26-15.82) than those randomly selected patients from anticoagulation clinics. As the majority (81%) of patients in the low-dose group possessed at least one or more of either CYP2C9*2 or CYP2C9*3 allele, they considered that the patients carrying these CYP2C9 variants may be more susceptible to bleeding complications than the genotype-unspecified randomly selected population. Ogg et al 25 reported a post hoc analysis of a prospective large-scale thrombosis prevention trial with low-intensity warfarin therapy performed in 5499 British men at high risk of ischemic heart disease: they found that the two patients with the homozygous CYP2C9*3 genotype had a significantly greater probability (ie, 100%) of developing bleeding complications than those with the homozygous wild-type CYP2C9 genotype (ie, 9%) during the initial 3 months of the trial. However, there was no evidence suggesting that the heterozygous carriers of CYP2C9*3 would be more susceptible to bleeding complications than those with homozygous for both groups wild-type CYP2C9 genotype (ie, 10%) during the initiation 3 months as well as through 3-4 years of the entire follow-up period. Recently, Higashi et al 31 conducted a retrospective cohort study where they analyzed the influence of the CYP2C9 genotypes on the anticoagulation responses and bleeding complications during warfarin therapy. They found that the patients with at least one CYP2C9 variant allele of either CYP2C9*2 or CYP2C9*3 took a longer time to achieve stable dosing of warfarin than those with the homozygous wild-type genotype (hazard ratio (HR), 0.65; 95% CI, 0.45-0.94) with the median difference of 95 days. In addition, the patients with at least one variant CYP2C9 allele had a greater risk of developing bleeding events during the initial 3 months of warfarin therapy (HR, 3.94; 95% CI, 1.29-12.06).
Maintenance phase
Aithal et al 23 reported that the patients requiring less than 1.5 mg/day of warfarin for attaining optimal anticoagulation response (the low-dose group) exhibited a higher incidence of serious and life-threatening bleeding episodes than those randomly selected patients from anticoagulation clinics (rate ratio (RR), 3.68; 95% CI, 1.43-9.50). In support of their findings were the subsequent studies conducted by other investigators 27, 31 demonstrating that patients with the heterozygous CYP2C9*2 or CYP2C9*3 genotype would carry a higher risk of bleeding complications during warfarin therapy: OR, 2.57; 95% CI, 1.16-5.73 27 and HR, 2.39; 95% CI, 1.18-4.86. 31 One of these studies 31 also showed that the carriers of CYP2C9*2 or CYP2C9*3 allele more frequently developed above-range or supratherapeutic INRs (44.0 for most patients and 44.5 for those with prosthetic valve replacement) with the HR of 1.4 (95% CI, 1.03-1.90).
In contrast, Taube et al 26 could not confirm the above findings in their study performed with a large number of patients (n ¼ 561) and a more extended period (the median of 2.38 years) of follow-up. Despite that their patients with the CYP2C9*2 and *3 variant alleles had a significantly reduced dose requirement as compared with those with the wild-type genotype (Table 1) Since Asians appear to be more sensitive to warfarin than Caucasians 2,3 as far as the maintenance dose is concerned, it is of great interest whether the CYP2C9 genotypes would have a significant effect on the susceptibility to bleeding complications of warfarin therapy in non-Caucasian populations. As there is a paucity of knowledge regarding this issue, it would be of value to carry out retrospective studies on this issue before embarking on prospective trials. However, prospective, long-term, controlled clinical studies should ultimately be performed to assess clinical implications of the CYP2C9 genotypes on the anticoagulation response and bleeding complications during the warfarin therapy in Asians and other non-Caucasian populations.
Collectively, it is suggested that patients with CYP2C9 variants, particularly CYP2C9*3 allele or a combination of CYP2C9*2 and CYP2C9*3 alleles would be vulnerable to above-range INRs, need more time to achieve stable warfarin dosing and longer hospitalization and have a higher risk of serious or life-threatening bleeding events than those with wild-type CYP2C9 genotype during the induction or dose-titration period of warfarin therapy.
EFFECTS OF CYP2C9 GENOTYPES ON (S)-WARFARIN METABOLISM
Within-population comparisons While numerous studies have been conducted to clarify the relation between the CYP2C9 genotypes and maintenance dose of warfarin, few of them have addressed the question whether CYP2C9 variants would be associated with altered in vivo metabolic activity toward any of the CYP2C9 substrate drugs. [10] [11] [12] [13] [14] [15] We were the first to report that Japanese patients with the heterozygous and homozygous CYP2C9*3 allele exhibited a 63 and 89%, reduced unbound oral clearance (CL po,u ) for (S)-warfarin, respectively, as compared with those with the homozygous wild-type CYP2C9 allele. 12, 13 As a significant gene-dose effect in CL po,u for (S)-warfarin by CYP2C9*3 variant was observed, we considered that the CYP2C9*3 variant may have a clinically significant impact on the anticoagulation response to warfarin even in a heterozygous genotype in Japanese patients.
Subsequently, we studied the effects of the CYP2C9 polymorphisms on CL po,u for (S)-warfarin in Caucasians using the same protocol as we used in the previous studies performed in Japanese patients. 12, 13 To our surprise, we observed no significant difference in CL po,u for (S)-warfarin between the Caucasian patients with the homozygous wild-type CYP2C9 genotype and those with the heterozygous CYP2C9*2 or CYP2C9*3 genotype. Nonetheless, a patient having a combined heterozygote of CYP2C9*2 and CYP2C9*3 (ie, CYP2C9*2/*3) had CL po,u for (S)-warfarin that was 70% lower than the mean value for those with the homozygous wild-type CYP2C9 genotype. 14 Loebstein et al 11 reported that the Jewish patients (n ¼ 156) with the CYP2C9*1/*2 and CYP2C9*1/*3 genotypes had 8 and 38% lower total (bound + unbound) oral clearance (CL po ) for warfarin than those with the CYP2C9*1/*1 genotype. Recently, Scordo et al 15 reported that there was a significant (Po0.01) difference in CL po,u for (S)-warfarin among the groups of patients with different CYP2C9 genotypes (ie, six possible combinations of CYP2C9*2 and CYP2C9*3 alleles) in 93 Italian patients. However, there was a substantial overlap in CL po,u for (S)-warfarin among the different genotype groups, so that 72% of the patients with the CYP2C9*1/*1 genotype showed CL po,u for (S)-warfarin in the same range as those carrying either CYP2C9*2 or CYP2C9*3 allele. Collectively, the magnitude of reduction in CL po,u for (S)-warfarin associated with the CYP2C9*1/*3 genotype as compared with the respective control values obtained from those with wild-type CYP2C9 genotype in the above two studies 11, 15 (ie, 38 and 48%, respectively) appears somewhat attenuated as compared with that we observed in Japanese patients (63%). 12, 13 The data obtained from the studies of Loebstein et al 11 and Scordo et al 15 agreed that the influence of CYP2C9*2 mutation on the in vivo warfarin metabolism assessed by CL po or CL po,u in humans appears less pronounced than that of CYP2C9*3.
Population differences in CYP2C9 activity and allelic frequencies of CYP2C9 variants There are substantial differences in the allelic frequencies of CYP2C9 variants, at least for CYP2C9*2 and CYP2C9*3 alleles, across different ethnic populations: the respective allelic frequencies of CYP2C9*2 and CYP2C9*3 in African-Americans (1-3.6% and 0.5-1.5%, respectively) and Asians (0% and 1.7-5%, respectively) tended to be lower than the corresponding values of Caucasians (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .1% and 5.3-10%, respectively). 8, 9 As the enzyme activities of CYP2C9 variant proteins are reduced as compared with the wild-type protein 42 at least in in vitro experiments, there is a possibility that the population differences in the allelic frequencies of distinct CYP2C9 variants may emerge as those in certain phenotypic traits of CYP2C9 (eg, CL po,u ). We have recently studied the population differences of hepatic CYP2C9 activity using CL po,u for (S)-warfarin as a specific in vivo probe for the CYP isoform between Caucasians and Japanese patients and found that the population mean for body weightnormalized CL po,u for (S)-warfarin obtained from Japanese patients was significantly greater than that for Caucasian patients.
14 Considering greater allelic frequencies of CYP2C9*2 and CYP2C9*3 in Caucasians than in Japanese patients, 8, 9 one may assume that population differences in the allelic frequencies of CYP2C9*2 and CYP2C9*3 between Caucasians and Japanese patients may account at least partly for the above-described population difference in the metabolic activity for (S)-warfarin. However, comparisons of CL po,u for (S)-warfarin between the genotype-matched Japanese patients and Caucasians with the homozygous wild-type CYP2C9 genotype revealed that Japanese patients still had a significantly greater body weight-normalized CL po,u than the Caucasians.
14 Collectively, previously recognized genetic polymorphisms of CYP2C9 cannot adequately account for the observed population differences in the in vivo CYP2C9 activity at least between Caucasians and Japanese patients.
Regarding population differences in the allelic frequencies of CYP2C9 variants, a recent report of Leung et al 32 deserves some comments. They studied the genetic polymorphisms of CYP2C9 in Chinese patients and found four novel single-nucleotide polymorphisms (SNPs) in CYP2C9 exon 4. In addition, they found that the patients with one of the SNPs (ie, a nucleotide change of 527A4C corresponding to an amino-acid substitution of 181Ile4Leu) may be associated with greater maintenance dose of warfarin and those with the other SNP (ie, 608T4G or 208Leu4Val) was associated with a lower warfarin dose than those with the wild-type genotype. However, caution must be exercised for interpreting their data, because their data may be flawed by inappropriate primer designs. We critically reappraised their findings using their primers originally reported by Stubbins et al 43 and the other primers by Sullivan-Klose et al 44 that were validated by us and others. [12] [13] [14] 16 We found that the nucleotide sequences of the PCR products amplified by the primers of Leung et al 32 and Stubbins et al 43 differed from those amplified by the latter primers 44 and the authentic DNA sequence of CYP2C9 exon 4. Using the latter PCR primers we found no SNPs in exon 4 of CYP2C9 in Japanese patients (unpublished data).
CYP2C9 genotypes and development of enzyme activity Since many CYP isoforms exhibit substantial ontogenic changes in their enzyme activity particularly during prepubertal period (o12 years), it is of great interest if the genetic polymorphism of CYP2C9 may influence the developmental changes in the CYP2C9 activity. In this context, we compared CL po,u for (S)-warfarin between prepubertal (1-11 years) and adult (37-76 years) Japanese patients with the CYP2C9*1/*1 or CYP2C9*1/ *3 genotypes. 45 The median CL po,u for (S)-warfarin obtained from the adult patients with the wild-type (CYP2C9*1/*1) genotype (ie, 667 ml/ min) was significantly greater than that obtained from the prepubertal patients with the corresponding genotype (ie, 367 ml/min), indicating a substantial development would take place for the activity of CYP2C9 in these subjects. In contrast, there was no significant difference in the median CL po,u for (S)-warfarin between prepubertal and adult patients with the CYP2C9*1/*3 genotype (ie, 213 and 212 ml/min, respectively), indicating that the development of CYP2C9 activity may be substantially attenuated in carriers of the CYP2C9*3 allele. However, because the numbers of prepubertal and adult patients with the CYP2C9*1/*3 allele were rather small (n ¼ 5 and 4, respectively) and no longitudinal follow-up was made for individual children with CYP2C9*1/*3 genotype, further studies are required to confirm our findings. At present, to our knowledge, no attempts have been made to study the effect of CYP2C9 variants on the development of CYP2C9 activity in Caucasians and other ethnic populations.
PHARMACOKINETIC CONSEQUENCES OF CYP2C9 POLYMORPHISMS Dose-response relation
We have already discussed the effects of CYP2C9 polymorphism on the maintenance dose of warfarin and the metabolic activity of CYP2C9. Here, we wish to afford a pharmacokinetic basis for these clinical findings. For many drugs the magnitude of the pharmacological response is a function of plasma unbound drug concentrations, because the unbound drug in plasma is assumed to be equilibrating with that in site(s) of action. Indeed, we previously demonstrated that there is a significant linear relation between Cu for (S)-warfarin and INR in Japanese patients undergoing long-term stable anticoagulation therapy with warfarin. 46 Clearance (CL) is a pharmacokinetic parameter that connects the dosing rate of a drug (D/t) with its steady-state plasma concentration according to the equation C pss ¼ (D/t)/ CL. Thus, assuming that there are no significant differences in the anticoagulation sensitivity to warfarin between patients with different CYP2C9 genotypes, the maintenance dose of warfarin for those with defective alleles of CYP2C9 (eg, CYP2C9*3) should be reduced largely in parallel with that observed in CL po,u in the respective populations in order to obtain comparable Cu and thereby INR.
Time to reach stable warfarin dosing
When a drug is administered intermittently at regular dosing intervals, the steady-state plasma concentration will be achieved after approximately 4 halflives (t 1/2 ) of the drug, regardless of doses or dosing intervals. Since the mean t 1/2 of (S)-warfarin obtained from randomly selected population (most likely having the CYP2C9*1/*1 genotype) is approximately 1 day, 47 it would take approximately 4 days to reach the steady-state plasma concentration of (S)-warfarin in patients with the CYP2C9*1/*1 genotype (Figure 1 ). On the other hand, a patient with a CYP2C9 variant associated with the reduced enzyme activity would require a longer time to attain the steady state of the warfarin disposition than those with the wild-type genotype. Assuming that the volume of distribution of warfarin is independent of CYP2C9 genotypes, the elimination t 1/2 of (S)-warfarin in patients with CYP2C9 variants will be prolonged in proportion to the reciprocal of the systemic As Caucasians and Japanese patients with the CYP2C9*1/*3 genotype possess a 38-48% and 63% lower CL po,u for (S)-warfarin than those with the CYP2C9*1/*1 genotype in the respective populations, their elimination t 1/2 for (S)-warfarin should be 1.6-1.9 and 2.7 times longer than that in those with the CYP2C9*1/*1 genotype (ie, 1 day). Therefore, Caucasian and Japanese patients with the CYP2C9*1/*3 genotype would require approximately 6-8 and 11 days, respectively, to reach the steady-state condition. Furthermore, because a Japanese patient having the homozygous CYP2C9*3 allele has an 89% lower CL po,u for (S)-warfarin than those with the homozygous CYP2C9*1 allele, 12 such a patient would require approximately 36 days to reach the steadystate plasma concentration of (S)-warfarin as well as stable INR status. As mentioned above, time required to reach steady state of a drug during intermittent administrations solely depends on its elimination t 1/2 , an adoption of a loading dose warfarin regimen (eg, 10 mg for a loading dose followed by 3.4 mg of a maintenance dose) will not help to shorten the time to achieve the steady-state condition for patients with the CYP2C9*3 allele. As shown in Figure 1 , when an average maintenance dose of warfarin (eg, 3.4 mg) is given to Japanese patients irrespective of their CYP2C9 genotypes, the resultant steady-state plasma (S)-warfarin concentrations for patients with the CYP2C9*1/*3 and CYP2C9*3/*3 genotypes would be 2.7 and 9.1 times greater than that obtained from a representative patient with the CYP2C9*1/*1 genotype.
The above simulation of the plasma (S)-warfarin concentrations-time courses in patients with different CYP2C9 genotypes would give us a further insight into the finding of Higashi et al 31 . They found that patients with one or more of CYP2C9*2 or *3 allele had longer time to achieve stable warfarin dosing with a mean difference of 95 days after the commencement of warfarin therapy than those with the homozygous CYP2C9 wildtype genotype. In their study, a common dosing protocol of warfarin was employed for their patients irrespective of patients' CYP2C9 genotypes.
Our pharmacokinetic simulation of the plasma concentration-time course of pharmacologically more active (S)-warfarin in patients with different CYP2C9 genotypes predicts that patients with CYP2C9*3 allele would exhibit a greater plasma concentration of (S)-warfarin and thereby exaggerated anticoagulation response to a standard warfarin dosing. In addition, because the patients with CYP2C9*3 allele have a longer t 1/
Risks of adverse drug reactions
It is commonly believed that patients receiving greater doses of a drug would be at higher risk to develop adverse drug reactions. Contradicting to this notion, lines of evidence indicate that patients receiving lower doses of warfarin tend to have a greater incidence of bleeding complications particularly during the initial phase of warfarin therapy. 23, 31 Our discussion about the effects of CYP2C9 polymorphisms on the in vivo pharmacokinetics of (S)-warfarin and on the disposition of vitamin K-dependent coagulation factors may explain at least partly an apparently paradoxical relation between the individualized maintenance dose of the drug and incidence of adverse drug reactions.
Loading dose of warfarin is often adopted in order to accelerate to elicit therapeutic anticoagulation response of the drug. However, based upon our simulation of the plasma concentration-time courses of (S)-warfarin in patients with different CYP2C9 genotypes ( Figure 1) we assume that the loading dose of warfarin may pose a greater risk of bleeding complications in patients with CYP2C9 variant alleles particularly around initial two or three doses of the drug as compared with those with the wild-type CYP2C9 genotype. When a loading dose regimen of warfarin is employed, plasma (S)-warfarin concentrations in the patients with the CYP2C9*1/*3 or CYP2C9*3/*3 genotype would rise Figure 1 Computer-assisted simulations for the plasma total (bound+unbound) (S)-warfarin concentration-time profiles following the intermittent administration of 3.4 mg of racemic warfarin a day in representative Japanese patients with CYP2C9*1/*1(thin line), CYP2C9*1/*3 (medium-bold line) and CYP2C9*3/*3 (bold line) genotypes following an oral dose of 3.4 mg/day. The symbols *, W and } represent plasma concentration-time curves for patients with CYP2C9*1/*1, CYP2C9*1/*3 and CYP2C9*3/*3 genotypes when a loading dose regimen of 10 mg followed by a maintenance dose of 3.4 mg/day was employed. The simulation was performed assuming that the representative patients with CYP2C9*1/*1, CYP2C9*1/*3 and CYP2C9*3/*3 genotypes had the total oral clearance for (S)-warfarin of 0.34, 0.11 and 0.034 l/h, respectively, 7.4 l for volume of distribution and an oral bioavailability of unity. The horizontal broken line represents the population mean value for the steady-state plasma (S)-warfarin concentration with an oral warfarin dose of 6.1 mg/day in Caucasians 53 and the solid line represents that with 3.4 mg/day in Japanese patients. CYP2C9 polymorphisms and warfarin therapy H Takahashi and H Echizen much higher than those with the wildtype genotype and thereby elicit a more extensive depletion of vitamin K-dependent coagulation proteins particularly F-VII with a short t 1/2 of 1.5-5 h.
In this context, it is also worth noting to remember that a rare complication of warfarin therapy, skin necrosis, has been reported to develop within 3-4 days of the initiation of warfarin therapy typically when a loading dose regimen of warfarin is employed in patients with heterozygous hereditary protein C deficiency. 48 Protein C is a vitamin K-dependent antithrombotic protein with a t 1/2 (6-8 h) shorter than most vitamin Kdependent clotting proteins. Thus, the administration of a loading dose of warfarin to patients with CYP2C9 variants may cause greater depletion in Protein C rather than vitamin K-dependent clotting proteins and give rise to hypercoagulability and thrombosis in the cutaneous microvasculature. To our knowledge, however, no information is available whether the patients developing skin necrosis by warfarin therapy would carry any of the CYP2C9 variants.
CL po,u for (S)-warfarin vs INR relation
As certain CYP2C9 variants are associated with the reduced CL po,u for (S)-warfarin, it is of interest to discuss about the effect of CYP2C9 polymorphisms on the relation between CL po,u for (S)-warfarin and INR. In our previous studies 46, 49 we found that there was a weak, albeit significant (Po0.05), correlation between Cu for (S)-warfarin and INR, an index of the anticoagulation response to warfarin, in Japanese patients who received warfarin with or without CYP2C9 inhibitors (ie, bucolome and benzbromarone) (Figure 2a) . The linear regression line obtained from the data was as follows:
where Cu(S) is the plasma unbound concentration of (S)-warfarin. The steady-state plasma unbound concentration of (S)-warfarin [Cu(S)] during an intermittent oral administration of racemic warfarin at a dose (D) is a function of oral dose of (S)-warfarin (D/2), a fraction of gastrointestinal absorption (F a ) of the drug, dosing interval (t) and unbound oral clearance for (S)-warfarin [CL po,u (S)]. Assuming a complete absorption of warfarin from the intestine (ie, F a ¼ 1), Cu(S) will be determined by the equation shown below:
Substituting Cu(S) obtained from Equation (2) into Equation (1), one can obtain the following equation:
Equation (3) indicates that INR is a function of D/t and CL po,u (S). In order to assess whether the above equation can fit actual data, we show the scatter plots of the data for CL po,u (S) and INR obtained from patients receiving a long-term stable dosing of warfarin alone and those receiving warfarin with bucolome ( Figure 2b) . 46 As the patients who received warfarin with bucolome, a potent inhibitor of CYP2C9, showed substantially reduced CL po,u (S) of o300 ml/min, we can inspect whether Equation (3) adequately describes the clinical data over a wide range of CL po,u (S). The data obtained from patients receiving warfarin alone (*) and those received warfarin with bucolome (K) largely distribute along the simulation curves. In order to facilitate readers' understanding, we also drew the simulated curves generated by substituting three different oral doses of warfarin (ie, 3.4, 1.75 and 0.4 mg a day) for D/t in Equation (3). These doses are the mean oral doses of warfarin obtained from Japanese patients with CYP2C9*1/*1, CYP2C9*1/*3 and CYP2C9*3/*3 genotypes. 13 The simulation curves clearly indicate that INR begins to rise precipitously as CL po,u (S) decreases o200 ml/min. Therefore, if warfarin therapy is initiated by a standard dosing regimen (eg, 3.4 mg/day of racemic warfarin once a day for Japanese patients) in all patients, those with the CYP2C9*1/*3 genotype having the mean CL po,u (S) of 212 ml/min 12 and those received bucolome having the mean CL po,u (S) of 107 ml/min may experience extremely prolonged INR and bleeding complications unless the 46 or benzbromarone (^) 49 (a, left). The solid line is the regression line for the overall data (ie, INR ¼ 0.235 Â Cu(S)+1.17, Po0.05) and broken lines depict the 95% confidence intervals of the data. The right figure (b) shows the scatter plots for the relation between unbound oral clearance for (S)-warfarin [CL po,u (S)] and INR obtained from patients receiving stable oral doses of warfarin alone (*) and those receiving warfarin with bucolome (K). 46 The thick, medium and thin solid curves represent the INR-CL po,u (S) relation in patients receiving 3.4, 1.75 and 0.4mg/day of racemic warfarin, respectively (see details in text). The data points corresponding to typical patients with the mean CL po,u (S) in heterozygote and homozygote of CYP2C9*3 are shown as open ($) and closed (%) stars, respectively, and that for the wild-type genotype is shown as the double circle (|). Since patients with reduced CL po,u (S) are located on ascending part of the hyperbolic function, they are more susceptible to develop precipitous prolongation of INR in response to a small variability in CL po,u (S) than those with normal metabolic activity who located on the horizontal part of the curve.
dose of the drug is reduced promptly. In addition, when we plot the mean CL po,u (S) data obtained from patients with CYP2C9*1/*1 (|), CYP2C9*1/*3 ($) and CYP2C9*3/*3 (%) genotypes, 13 it becomes evident that the doses of warfarin for the patients with CYP2C9*3 allele are reduced to 1.75 and 0.4 mg/day to achieve a target INR of 1.5-2.0 that can be obtained with the dose of 3.4 mg/ day for those with the wild-type CYP2C9 genotype. Figure 2b also indicates that patients with reduced CL po,u (S) are more susceptible to precipitous prolongation of INR in response to a small reduction in CL po,u (S) or the hepatic CYP2C9 activity than those with normal metabolic activity. In this context, patients with defective CYP2C9 alleles may be particularly vulnerable to bleeding complications due to metabolic inhibition. For instance, a representative Japanese patient with the wild-type CYP2C9 genotype having CL po,u (S) of 625 ml/ min 13 (|) will exhibit INR of 1.6 at an oral dose of warfarin of 3.4 mg/day (Figure 2b) . If the patient is given a CYP2C9 inhibitor that reduces CL po,u (S) by 50% (ie, 300 ml/min reduction from 625 to 325 ml/min), his or her INR would increase from 1.6 to 2.0. In contrast, in a typical Japanese patient with the CYP2C9*3/*3 genotype (%) exhibiting INR of 1.7 at a warfarin dose of as low as 0.4 mg/day, only a small reduction of CL po,u (S) (eg, 30 ml/min) would be associated with a comparable increase in INR from 1.7 to 2.2. As such, the genetic polymorphism of CYP2C9 may increase the susceptibility to unstable INR status thereby bleeding complications. Figure 3 shows the relation between plasma concentrations of prothrombin fragments 1+2 (ie, F 1+2 ) and INR obtained from Japanese patients receiving a long-term warfarin therapy. As plasma concentration of F 1+2 is associated with thrombin generation, the administration of warfarin suppresses plasma F 1+2 concentrations. In addition, there is an apparently hyperbolic relation between the parameters (Figure 3 ) as shown in a previous study. 50 As patients having defective CYP2C9 variants or receiving coadministration of CYP2C9 inhibitors would have higher plasma (S)-warfarin concentrations and thereby reduced plasma F 1+2 concentrations, they are likely more susceptible to develop a large variability in INR as compared with those with normal metabolic activity for CYP2C9.
Susceptibility to bleeding complication and instability of INR
To validate our theoretical consideration made in Figures 2b and 3 , we analyzed the clinical data obtained from a retrospective cohort study assessing the relation between CL po,u (S) and intrapatient variability of INR over 1 year during warfarin therapy (unpublished data). We sorted the data according to CL po,u (S) and calculated an index of intraindividual variability of INR defined as the percentage of the difference between the maximum and minimum INR normalized to the minimum INR value (ie, %(INR max ÀINR min )/INR min Â 100) within the same subjects. Since CL po,u (S) obtained from patients distributed widely, we arbitrarily grouped patients into those receiving a CYP2C9 inhibitor (ie, bucolome), those with CL po,u (S) o 270 ml/min (arbitrarily defined as the low clearance group) and those with CLpo,u (S) of 41000 ml/min (the high clearance group). Those receiving bucolome was shown to have the mean CL po,u of 107 ml/min (n ¼ 21). 46 As shown in Figure 4 , statistical comparisons for the variance obtained from the respective groups indicated that SDs of percentages relative changes in INR obtained from the bucolome and the low clearance groups were significantly greater than that obtained from the high clearance group. This finding implies that patients with low CL po,u (S) may be associated with a greater variability in INR than those with high CL po,u (S). Our data would also account for the previous findings indicating that patients with defective CYP2C9 variants are associated with a greater chance of developing bleeding complications and/or unstable INR status. 31 Obviously, further studies with a greater number of patients should be performed under a prospective Figure 3 The relation between plasma concentrations of prothrombin fragment 1+2 (F 1+2 ), a marker of thrombin generation, and INR obtained from Japanese (K) and Caucasian (*) patients receiving stable oral doses of warfarin. Note that there is a quasihyperbolic relation between the two parameters, suggesting a precipitous prolongation of INR in response to a small variability in the thrombin generation where the generation of thrombin is more extensively suppressed. This implies that patients with CYP2C9*3 or those with coadministration of CYP2C9 inhibitor may be more susceptible to unstable INR response than those with less intensive anticoagulation suppression (see details in text). CYP2C9 polymorphisms and warfarin therapy H Takahashi and H Echizen experimental protocol in order to confirm our hypothetical consideration made based upon a rather limited number of patients.
OTHER FACTORS CONTRIBUTING TO VARIABLE RESPONSE TO WARFARIN
While the genetic polymorphisms of CYP2C9 is an important factor associated with interindividual variability of CL po,u (S) and thereby that in the anticoagulation response to warfarin, other factors such as age, 33 drug interaction with concomitantly administered drugs, 46, 49 food and other undefined factors are also considered to be involved in the variable anticoagulation response to the drug. It has been suggested that an age-related reduction in liver size 51 would account for reductions in the metabolic activity of warfarin. We have already discussed the effects of concomitant administration of CYP2C9 inhibitors (eg, bucolome, benzbromarone) on the dose, CL po,u (S) and interindividual variability of INR. It is worth noting that the coadministration of a potent CYP3A4 inhibitor (eg, diltiazem) does not have influence on the anticoagulation response to warfarin. 52 Abernethy et al 52 demonstrated that the coadministration of oral diltiazem 120 mg three times daily produced a small (20%) reduction in the total (bound + unbound) clearance of (R)-warfarin, but not (S)-warfarin, after intravenous administration of warfarin as compared with the respective control values. Because the anticoagulation of (R)-warfarin is three to five time less potent than (S)-warfarin and CYP3A4 is involved only partly in the metabolism of (R)-warfarin, a potent inhibition of CYP3A4 may not necessarily be associated with a significant change in the INR status. Most of the important drug interactions with warfarin that were associated with fatal or severe bleeding complications were attributable to CYP2C9 inhibitors (eg, phenylbutazone, sulfinpyrazone, bucolome).
Pharmacodynamic factors associated with a large interindividual variability of warfarin response deserve some comments. Excessive consumption of vitamin K-rich diets (eg, green vegetables) has been claimed to attenuate the anticoagulation effect of warfarin. 34 In contrast, the administration of certain antibiotics that interfere with the production of vitamin K by gut flora has been suggested to exaggerate the anticoagulation response to warfarin. These data suggest that variability of vitamin K intake would be an important factor associated with the intraindividual variability of INR in patients receiving warfarin. It has been suggested that the interindividual variability in the expression of calumenin (ie, an inhibitory protein for VKOR complex) in the liver may have a pivotal role in the sensitivity of VKOR and vitamin Kdependent g-carboxylation system in rats 38 and possibly in humans. Genetic polymorphisms of vitamin K-dependent coagulation factors may also affect the responsiveness of warfarin. As there is a substantial population difference (Asians vs Caucasians) and disease-specific difference (eg, those with prosthetic valve) in the target INR, there must be unknown pharmacodynamic factor(S) associated with variable response to warfarin. Collectively, there is a relative paucity of knowledge for pharmacodynamic parameters as compared with that for pharmacokinetic parameters associated with the interindividual variability of anticoagulation response to warfarin.
CONCLUSION
In the present article we have summarized the implications of CYP2C9 polymorphisms in the pharmaco- The patients who received a CYP2C9 inhibitor, bucolome, are shown as closed circle (K, BM, n ¼ 10), and those having CL po,u for (S)-warfarin of o270 ml/min (~, the low clearance group; low CL, n ¼ 7) and those with CL po,u for (S)-warfarin of 41000 ml/min (*, the high clearance group; high CL, n ¼ 7) were sorted out from the overall data. The mean CL po,u (S) for the BM group was 107768 ml/ min. Note that the BM and the low CL groups exhibit significantly greater variabilities in INR than the high CL group. **Po0.01 as compared with the high CL group based upon the statistical comparisons for the SDs obtained from the respective groups.
kinetics of pharmacologically more active (S)-enantiomer of warfarin in the light of its contribution to the interindividual variability of warfarin dosage, risks of bleeding complications and stability of anticoagulation response. Based upon the accumulated information, consensus appears to emerge that patients with either heterozygous or homozygous CYP2C9*3 variant and those of combined heterozygote of CYP2C9*2 and *3 (ie, CYP2C9*2/*3) would have a substantially reduced dose requirement for the maintenance dose of warfarin, need longer time to achieve stable warfarin dosing and carry higher risks of developing above-range INRs associated with serious bleeding complications, particularly during the early phase of warfarin therapy as compared with those with the homozygous wild-type CYP2C9 genotype. There is a possibility that different CYP2C9 variants may have different magnitude of effect on in vitro and in vivo metabolic activity for this CYP isoform. While both CYP2C9*2 and CYP2C9*3 variants have been implicated with substantially reduced enzyme activities in in vitro experiments, the effect of CYP2C9*3 mutation on the in vivo clearance of CYP2C9 substrate (eg, (S)-warfarin) may be greater than that of CYP2C9*2. While Japanese patients with the CYP2C9*1/*3 genotype were associated with markedly reduced CL po,u for (S)-warfarin as compared with those with the homozygous wild-type CYP2C9 genotype, Caucasian patients with either the heterozygous CYP2C9*2 or CYP2C9*3 variant would exhibit only marginal reduction in CL po,u for (S)-warfarin. 14, 15 The population mean of body weight-normalized CL po,u for (S)-warfarin obtained from Japanese patients was greater than that obtained from Caucasians.
14 Caucasians have greater allelic frequencies of CYP2C9*2 and CYP2C9*3 than Asians and AfricanAmericans indicating substantial population differences in the genetic polymorphism of this CYP isoform (Tables 1 and 2 ). To our surprise, however, the population difference in the mean CL po,u for (S)-warfarin was not fully accounted for a greater frequencies of CYP2C9 variants alleles in Caucasians than Japanese patients, because the mean CL po,u obtained from Japanese patients genotyped as having homozygous CYP2C9*1 allele was still significantly greater than that obtained from Caucasian patients with the corresponding CYP2C9 genotype. In this context, further studies are necessary to explore concealed parameters (eg, unidentified functionally defective variants in the coding regions and/or noncoding regions of CYP2C9, food and environmental factors) that may account for this apparently paradoxical finding.
The CYP2C9 polymorphisms may also have substantial influence on the developmental changes in the metabolic activity of this CYP isoform. Japanese children with the CYP2C9*1/*3 genotype appear to show an attenuated increase in the in vivo CYP2C9 activity measured by CL po,u for (S)-warfarin, while those with the homozygous wild-type genotype exhibit substantial increase in this parameter particularly during prepubertal period (o12 years). It remains to be confirmed if a similar finding can be observed in different ethnic populations.
As the magnitude of reduction in CL po,u for (S)-warfarin associated with CYP2C9*3 polymorphism largely parallels with that observed in the maintenance dose of racemic warfarin, there is a possibility that the genotyping of CYP2C9 prior to the warfarin therapy may be useful for estimating individualized initial dose of the drug. Simulations of plasma concentrationtime curves of (S)-warfarin in patients with different genotypes of CYP2C9*3 variant given a standard dose of the drug furnish a plausible explanation for the clinical observations that patients with CYP2C9 variants take longer to achieve a stable warfarin response and are more susceptible to develop above-range INR and bleeding complications particularly during the early phase of warfarin therapy.
In addition, because the relation between CL po,u for (S)-warfarin and INR is hyperbolic, patients with reduced CYP2C9 activity due to genetic polymorphism of CYP2C9 or coadministration of CYP2C9 inhibitor may more likely develop precipitous prolongation of INR in response to a small reduction in CL po,u for (S)-warfarin as compared with those with normal CYP2C9 activity. The fact that there is a quasi-hyperbolic relation between plasma concentrations of F 1+2 (ie, a marker of thrombin generation) and INR also suggests a greater fluctuation of INR at a greater anticoagulation status. In this context, the genotyping of CYP2C9 variants may be useful to circumvent unexpected severe adverse reactions of warfarin.
Pharmacodynamic parameters associated with the interindividual variability in the sensitivity to warfarin include genetic polymorphisms of VKOR-related system or vitamin Kdependent coagulation proteins, aging, variable intake of vitamin K and other unidentified environmental factors. To determine whether a routine genomic screening of CYP2C9 for patients undergoing warfarin therapy would be cost-effective, further studies are required to quantify the contribution of the CYP2C9 polymorphisms to the overall inter-and intrapatient variability in the INR response to warfarin relative to those attributable to all other genetic, clinical and environmental variables.
